A novel adenoviral hybrid-vector system carrying a plasmid replicon for safe and efficient cell and gene therapeutic applications

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e83-

  Voigtlander, Richard ^a,d   Haase, Rudolf ^a   Mück Hausl, Martin ^a   Zhang, Wenli ^a,c   Boehme, Philip ^c   Lipps, Hans Joachim ^c   Schulz, Eric ^c   Baiker, Armin ^b   Ehrhardt, Anja ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b BAVARIAN HEALTH AND FOOD SAFETY AUTHORITY   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adenovirus; PEPito; Persistent transgene expression; Plasmid replicon

Indexed keywords

ADENOVIRUS VECTOR; DNA; EXTRACHROMOSOMAL DNA; HIGH CAPACITY ADENOVIRAL VECTOR; HYBRID PROTEIN; PEPITO PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; EPISOME; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYBRID GENE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REPLICON; SOMATIC CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 84878861313     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.11     Document Type: Article

References (50)

1. Thomas, C.E., Ehrhardt, A. & Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358 (2003). (Pubitemid 36538359)
2. Ehrhardt, A., Xu, H. & Kay, M.A. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J. Virol. 77, 7689-7695 (2003). (Pubitemid 36734541)
3. Rauschhuber, C., Noske, N. & Ehrhardt, A. New insights into stability of recombinant adenovirus vector genomes in mammalian cells. Eur. J. Cell Biol. 91, 2-9 (2012).
4. Recchia, A., Perani, L., Sartori, D., Olgiati, C. & Mavilio, F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10, 660-670 (2004). (Pubitemid 39272855)
5. Gonçalves, M.A., Holkers, M., van Nierop, G.P., Wieringa, R., Pau, M.G. & de Vries, A.A. Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system. PLoS ONE 3, e3084 (2008).
6. Hausl, M.A. et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol. Ther. 18, 1896-1906 (2010).
7. Yant, S.R., Ehrhardt, A., Mikkelsen, J.G., Meuse, L., Pham, T. & Kay, M.A. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. 20, 999-1005 (2002).
8. Ehrhardt, A., Yant, S.R., Giering, J.C., Xu, H., Engler, J.A. & Kay, M.A. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol. Ther. 15, 146-156 (2007). (Pubitemid 46043660)
9. Biasco, L., Baricordi, C. & Aiuti, A. Retroviral integrations in gene therapy trials. Mol. Ther. 20, 709-716 (2012).
10. Kreppel, F. & Kochanek, S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J. Virol. 78, 9-22 (2004). (Pubitemid 37549715)
11. Gil, J.S., Gallaher, S.D. & Berk, A.J. Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice. Gene Ther. 17, 1288-1293 (2010).
12. Dorigo, O. et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J. Virol. 78, 6556-6566 (2004). (Pubitemid 38715953)
13. Tan, B.T., Wu, L. & Berk, A.J. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J. Virol. 73, 7582-7589 (1999). (Pubitemid 29383242)
14. Palmer, D.J. & Ng, P. Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 16, 1-16 (2005). (Pubitemid 40250327)
15. Brunetti-Pierri, N. et al. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum. Gene Ther. 16, 811-820 (2005). (Pubitemid 40982330)
16. Brunetti-Pierri, N. et al. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol. Ther. 17, 327-333 (2009).
17. Ehrhardt, A., Xu, H., Dillow, A.M., Bellinger, D.A., Nichols, T.C. & Kay, M.A. A genedeleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102, 2403-2411 (2003). (Pubitemid 37193576)
18. Chuah, M.K. et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101, 1734-1743 (2003). (Pubitemid 36237568)
19. Kiang, A. et al. Fully deleted adenovirus persistently expressing GAA accomplishes longterm skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice. Mol. Ther. 13, 127-134 (2006). (Pubitemid 41763490)
20. Brown, B.D., Shi, C.X., Powell, S., Hurlbut, D., Graham, F.L. & Lillicrap, D. Helperdependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103, 804-810 (2004). (Pubitemid 38129536)
21. Ehrhardt, A. & Kay, M.A. A new adenoviral helper-dependent vector results in longterm therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99, 3923-3930 (2002). (Pubitemid 35332030)
22. Schiedner, G. et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18, 180-183 (1998). (Pubitemid 28082470)
23. Haase, R. et al. pEPito: a significantly improved non-viral episomal expression vector for mammalian cells. BMC Biotechnol. 10, 20 (2010).
24. Baiker, A. et al. Mitotic stability of an episomal vector containing a human scaffold/matrixattached region is provided by association with nuclear matrix. Nat. Cell Biol. 2, 182-184 (2000).
25. Piechaczek, C., Fetzer, C., Baiker, A., Bode, J. & Lipps, H.J. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res. 27, 426-428 (1999). (Pubitemid 29210004)
26. Bode, J. et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 255, 195-197 (1992).
27. Jenke, A.C. et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl. Acad. Sci. U.S.A. 101, 11322-11327 (2004). (Pubitemid 39038345)
28. Stehle, I.M., Scinteie, M.F., Baiker, A., Jenke, A.C. & Lipps, H.J. Exploiting a minimal system to study the epigenetic control of DNA replication: the interplay between transcription and replication. Chromosome Res. 11, 413-421 (2003). (Pubitemid 37041202)
29. Stehle, I.M., Postberg, J., Rupprecht, S., Cremer, T., Jackson, D.A. & Lipps, H.J. Establishment and mitotic stability of an extra-chromosomal mammalian replicon. BMC Cell Biol. 8, 33 (2007).
30. Jenke, B.H. et al. An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo. EMBO Rep. 3, 349-354 (2002). (Pubitemid 34467605)
31. Schaarschmidt, D., Baltin, J., Stehle, I.M., Lipps, H.J. & Knippers, R. An episomal mammalian replicon: sequence-independent binding of the origin recognition complex. EMBO J. 23, 191-201 (2004). (Pubitemid 38165759)
32. Jager, L., Hausl, M.A., Rauschhuber, C., Wolf, N.M., Kay, M.A. & Ehrhardt, A. A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat. Protoc. 4, 547-564 (2009).
33. Hillgenberg, M., Tönnies, H. & Strauss, M. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4- kilobase genomic stuffer. J. Virol. 75, 9896-9908 (2001). (Pubitemid 32900124)
34. Shayakhmetov, D.M., Li, Z.Y., Ternovoi, V., Gaggar, A., Gharwan, H. & Lieber, A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 77, 3712-3723 (2003). (Pubitemid 36297290)
35. Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258-1266 (1999). (Pubitemid 29359019)
36. Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735-1737 (1999). (Pubitemid 29328217)
37. Müther, N., Noske, N. & Ehrhardt, A. Viral hybrid vectors for somatic integration - are they the better solution? Viruses 1, 1295-1324 (2009).
38. Tao, Q., Young, L.S., Woodman, C.B. & Murray, P.G. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front. Biosci. 11, 2672-2713 (2006). (Pubitemid 43806572)
39. Young, L.S. & Rickinson, A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757-768 (2004). (Pubitemid 39331148)
40. Harui, A., Suzuki, S., Kochanek, S. & Mitani, K. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73, 6141-6146 (1999). (Pubitemid 29274908)
41. Stephen, S.L., Sivanandam, V.G. & Kochanek, S. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J. Gene Med. 10, 1176-1189 (2008).
42. Stephen, S.L. et al. Chromosomal integration of adenoviral vector DNA in vivo. J. Virol. 84, 9987-9994 (2010).
43. Jager, L. & Ehrhardt, A. Persistence of high-capacity adenoviral vectors as replicationdefective monomeric genomes in vitro and in murine liver. Hum. Gene Ther. 20, 883-896 (2009).
44. Leight, E.R. & Sugden, B. Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event. Mol. Cell. Biol. 21, 4149-4161 (2001). (Pubitemid 32565297)
45. Chen, Z.Y., Yant, S.R., He, C.Y., Meuse, L., Shen, S. & Kay, M.A. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol. Ther. 3, 403-410 (2001). (Pubitemid 32514657)
46. Sharma, A., Bangari, D.S., Tandon, M., Pandey, A., HogenEsch, H. & Mittal, S.K. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386, 44-54 (2009).
47. Mizuguchi, H. & Kay, M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9, 2577-2583 (1998). (Pubitemid 29004630)
48. Mizuguchi, H. & Kay, M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10, 2013-2017 (1999). (Pubitemid 29387915)
49. Shayakhmetov, D.M. et al. Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J. Virol. 78, 10009-10022 (2004). (Pubitemid 39187119)
50. Palmer, D. & Ng, P. Improved system for helper-dependent adenoviral vector production. Mol. Ther. 8, 846-852 (2003). (Pubitemid 37527461)